What to expect after starting treatment: Realistic timelines and monitoring
Listen to this article as a podcast episode
August 20, 2026 · 20:50
For men with documented hypogonadism, the effects of testosterone therapy arrive in stages: sexual interest can improve within weeks, erections and mood take months, and body composition and bone change over many months to years.[1] Follow-up labs matter because symptom change without biochemical confirmation can be misleading, and lab improvement without symptom benefit may mean the original diagnosis was incomplete.
Find the cause before treating it
Choose a lab panel and get a clinical review with clear next steps.
Key takeaways
- In men who meet the diagnostic criteria, testosterone therapy tends to improve sexual interest within weeks, while erections, mood, body composition and bone respond over months to years. Enclomiphene works by raising LH, so its effect is judged by testosterone, LH and symptoms together.
- Hypogonadism is diagnosed from persistent symptoms plus confirmed low testosterone. A low number alone is not a diagnosis, and symptoms alone are not enough either.
- Position statements and reviews describe a first follow-up visit at about 3 months, then checks every 6 to 12 months, with testosterone, hematocrit and PSA measured alongside symptoms.
- Rising hematocrit is the most common adverse effect of TRT. The effect on red cell production is evident at about 3 months and peaks at 9 to 12 months, which is why it is checked throughout follow-up.
- Bone density is assessed during follow-up in men with bone risk or severe hypogonadism. Bone responds slowly, so an early scan says little about whether treatment is working.
How fast treatment starts working
Testosterone therapy does not act on every symptom at once. A 2011 review in the European Journal of Endocrinology found that effects on sexual interest appear after about 3 weeks and plateau at about 6 weeks, changes in erections and ejaculation can take up to 6 months, and effects on depressive mood become detectable after 3 to 6 weeks, with a maximum after 18 to 30 weeks.[1] According to the same review, changes in fat mass, lean mass and muscle strength occur within 12 to 16 weeks and stabilize at 6 to 12 months, while effects on bone are detectable after 6 months and continue for at least 3 years.[1]
Men also need the right diagnosis before any timeline estimate is meaningful. Male hypogonadism is a clinical syndrome, which means persistent symptoms plus biochemical evidence of deficiency. If that definition is unfamiliar, see What is low testosterone? The clinical definition most men (and many doctors) get wrong. Men treated without meeting clinical and laboratory criteria should not expect the results seen in trials.
TRT timeline by domain
According to the Testosterone Trials, a 2016 New England Journal of Medicine study of 790 men aged 65 or older with low testosterone and symptoms, one year of testosterone gel increased sexual activity, sexual desire and erectile function compared with placebo and produced slightly better mood, with no benefit for vitality or walking distance.[2]
| Domain | Typical TRT timeline | Typical Enclomiphene timeline | What to verify at 3 months |
|---|---|---|---|
| LH and testosterone response | Exogenous testosterone raises serum testosterone quickly, but symptom benefit still takes time | LH and FSH rise, and the body’s own testosterone rises with them | Objective biochemical response on follow-up labs |
| Sexual symptoms | Interest within about 3 to 6 weeks; erections up to 6 months | Depends on the testosterone response; less studied than TRT | Libido, erections, morning erections, satisfaction |
| Mood and energy | Mood changes detectable after 3 to 6 weeks, maximum after 18 to 30 weeks | Less studied; follows the hormone and symptom response | Whether symptoms are improving in a clinically meaningful way |
| Body composition | Begins within 12 to 16 weeks, stabilizes at 6 to 12 months | Not well studied; lifestyle change contributes | Waist circumference, body weight, lean and fat mass trend |
| Bone density | Detectable after 6 months, continues for years | Not studied as a short-term endpoint | DEXA if indicated |
Why Enclomiphene looks different
Enclomiphene raises testosterone by stimulating the hypothalamic pituitary testicular axis rather than replacing testosterone from outside the body. It blocks estrogen receptors in the hypothalamus, which increases GnRH and LH release.
LH and FSH are pituitary hormones that tell the testes to produce testosterone and sperm. In two phase III trials in overweight men with secondary hypogonadism, 16 weeks of enclomiphene raised testosterone along with LH and FSH and maintained sperm concentration, whereas topical testosterone suppressed LH and FSH and lowered sperm concentration.[3] This mechanism only works when the testes can still respond, so enclomiphene is not appropriate for primary hypogonadism.
What results are realistic over the first year
The earliest and most consistent treatment gains are sexual, while body composition and bone effects take longer to emerge.[1] [2]
Evidence is also uneven across symptoms. According to the 2023 EMAS position statement on TRT in older men, TRT may be offered to men with severe hypogonadism and erectile dysfunction to improve sexual desire, erectile and orgasmic function, and may be considered for selected men with persistent mild depressive symptoms, but it should not be used routinely to improve physical function or cognition because of a lack of data.[4]
Sexual function improves first
Sexual symptoms are the most consistent responders. A 2026 review in European Urology concluded that testosterone therapy improves sexual function in men with testosterone deficiency.[5] Within that domain, desire tends to respond within weeks, while erections can take up to 6 months.[1]
That does not mean all erectile dysfunction resolves with testosterone alone. PDE5 inhibitors are medicines such as tadalafil that improve penile blood flow. Men with severe erectile dysfunction often need combined management because vascular, neurologic and psychological causes can coexist even when testosterone deficiency is real. TRT is more likely to help hormone-related erectile dysfunction than advanced vascular disease.
Body composition changes are slower
Changes in fat mass, lean mass and muscle strength begin within 12 to 16 weeks of treatment and largely stabilize at 6 to 12 months, with marginal change continuing over years.[1] Because muscle gained can offset fat lost, body weight may change little even when body composition improves. Waist circumference, body composition and function are better guides than the scale.
Mood, energy, and bone need patience
A 2019 JAMA Psychiatry meta-analysis of 27 randomized trials including 1,890 men found that testosterone treatment was associated with a small reduction in depressive symptoms compared with placebo, with stronger effects at higher doses in carefully selected samples.[6] The Testosterone Trials also found slightly better mood and lower severity of depressive symptoms.[2] Mood effects can become detectable after 3 to 6 weeks but may not reach their maximum until 18 to 30 weeks.[1]
Cognition and vitality are different. In the Testosterone Trials, testosterone had no significant benefit on vitality,[2] and the EMAS statement advises against routine use to improve cognition because of a lack of data.[4] If fatigue or cognitive fog does not improve, another diagnosis may be driving the complaint.
Bone changes are the slowest clinically relevant outcome. BMD, or bone mineral density, is a measure of bone strength. The 2026 European Urology review concluded that testosterone therapy improves bone mineral density,[5] with effects detectable after about 6 months and continuing for at least 3 years.[1] Fracture reduction has not been shown in trials, and the EMAS statement places TRT alongside proven osteoporosis treatment, not in place of it.[4]
What the TRT monitoring protocol should include
The EMAS position statement recommends follow-up at 3, 6 and 12 months after starting TRT and at least yearly thereafter, with assessment of clinical response and measurement of total testosterone, hematocrit and PSA.[4] The 2026 European Urology review describes follow-up at 3 months and every 6 to 12 months thereafter, adjusted to clinical response and safety.[5]
Follow-up labs answer three separate questions. First, has testosterone reached the target range. Second, is treatment causing harm. Third, are symptoms improving in the domains most likely to respond. The 2025 European Association of Urology guidelines emphasize appropriate indications and structured follow-up for testosterone therapy in late-onset hypogonadism.[7]
Core safety and response markers
Hematocrit is the percentage of blood volume made up by red blood cells, and a rising hematocrit is the most common adverse effect of TRT. Testosterone’s effect on red cell production is evident at 3 months and peaks at 9 to 12 months.[1] PSA, or prostate specific antigen, is a blood marker used in prostate monitoring. On treatment it rises marginally and plateaus at about 12 months, and the 2011 review attributes later increases mainly to aging, although a rising PSA still needs evaluation.[1] Reviews cite guideline recommendations to keep testosterone in the mid-normal range, about 450 to 600 ng/dL, and to monitor hematocrit, PSA and metabolic parameters.[5] Lipid and glycemic markers matter most in men with obesity, metabolic syndrome or type 2 diabetes. BMI, waist circumference, blood pressure and a structured symptom review translate laboratory change into clinical reality.
| What to monitor | Why it matters | Practical checkpoint |
|---|---|---|
| Testosterone level | Confirms biochemical response and helps explain success or failure | About 3 months, then every 6 to 12 months |
| Hematocrit | Detects erythrocytosis, the most common TRT adverse effect | About 3 months, then every 6 to 12 months |
| PSA when indicated | Provides prostate surveillance during treatment | Baseline, 3 months, then per age, risk and clinician judgment |
| Lipid and glycemic profile | Tracks cardiometabolic status, especially in functional hypogonadism | Baseline, then during follow-up when clinically relevant |
| BMI and waist circumference | Shows whether body composition is actually moving | At each follow-up visit |
| Blood pressure | Tracks overall cardiovascular safety | At each follow-up visit |
| Structured symptom review | Determines whether the treatment is delivering meaningful benefit | At each follow-up visit |
When bone monitoring is needed
DEXA, short for dual energy X ray absorptiometry, measures bone density. The EMAS statement includes assessment of bone density or quality in the follow-up of older men on TRT.[4]
This is most relevant when severe hypogonadism, previous fragility fracture, osteopenia, osteoporosis or diabetes increases concern about bone loss. Bone effects only become detectable after about 6 months and continue for years,[1] so repeat scans are spaced well apart and an early scan is not a useful measure of whether treatment is working.
How follow up labs are interpreted when progress stalls
When symptoms have not improved, the first question is whether testosterone actually reached the target range, which guidelines place in the mid-normal range of about 450 to 600 ng/dL.[5]
A man who never met diagnostic criteria at baseline, or whose biochemical response remains inadequate, should not expect the benefits shown in trials. Treatment decisions rest on symptoms plus objective deficiency. A low number alone is not enough, and symptoms alone are not enough either.
Erection changes can take up to 6 months to appear.[1] If erections have not improved by then despite testosterone in the target range, other causes of sexual dysfunction should be investigated. The EMAS statement supports TRT for sexual function mainly in men with severe hypogonadism,[4] and vascular disease, neuropathy, medication effects and psychological factors may be the real reason progress has stalled.
If mood has not improved after testosterone normalization, a primary psychiatric condition may be the main driver. The 2019 meta-analysis found only a small average benefit and called for trials with depression as the primary end point,[6] and the EMAS statement considers TRT only for selected men with persistent mild depressive symptoms, combined with standard care for depression.[4]
When progress is disappointing, revisit the original workup. Free testosterone is particularly important because men with high SHBG can have low free testosterone despite an acceptable total testosterone. It is most reliably measured by equilibrium dialysis, ideally with LC-MS/MS, or calculated from total testosterone, SHBG and albumin; direct immunoassays for free testosterone are unreliable. LH and FSH should also have been checked before treatment. Without them, there is no way to tell whether the man had primary hypogonadism, which points toward replacement, or secondary hypogonadism, in which the testes are intact and a treatment that raises LH, such as enclomiphene, is an option. For more on that distinction, see Primary vs secondary hypogonadism: where the problem starts and why it changes everything and The complete low testosterone testing guide: what to order, when to test, and how to read results.
How fertility plans change treatment expectations
Fertility should be discussed before any treatment starts. According to the EMAS position statement, TRT is contraindicated in hypogonadal men actively seeking fertility treatment,[4] because external testosterone suppresses LH, FSH and sperm production. In the phase III enclomiphene trials, sperm concentration was maintained on enclomiphene and fell on topical testosterone.[3]
A man who starts TRT and later wants children may need to stop it and use gonadotropin therapy with hCG, often combined with FSH, to restore sperm production. Recovery can take months to more than a year and is not guaranteed, so it belongs in the consent discussion before treatment, not after the fact.
For a man with secondary or functional hypogonadism, starting with enclomiphene when appropriate can avoid that problem, because it stimulates the body’s own testosterone production through the existing axis and no treatment switch is needed when conception becomes the goal. For men who do not need immediate fertility treatment but want to keep the option open, enclomiphene is often preferred over TRT and hCG for that reason. For a fuller comparison, see Alternatives to TRT: Enclomiphene, hCG, lifestyle, and fertility preserving options.
What long term safety data shows
In the TRAVERSE trial, testosterone therapy was noninferior to placebo for major cardiovascular events over a mean follow-up of 33 months in 5,246 men.[8]
TRAVERSE, published in the New England Journal of Medicine in 2023, enrolled men aged 45 to 80 with symptoms of hypogonadism, low testosterone and preexisting or high risk of cardiovascular disease. The composite of cardiovascular death, myocardial infarction or stroke occurred in 7.0% of men on testosterone and 7.3% on placebo, although atrial fibrillation, acute kidney injury and pulmonary embolism were more frequent with testosterone.[8] Because men were followed for a mean of 33 months, the trial cannot exclude effects that appear only after longer treatment, which is why TRT is managed as an ongoing, monitored therapy.[8] Reviews also report no increase in prostate cancer risk with testosterone therapy.[5]
Safety data also sharpen expectations about what TRT does not do. In a TRAVERSE substudy, testosterone did not significantly reduce progression from prediabetes to diabetes and did not increase glycemic remission in men who already had diabetes.[9] Men with prediabetes or diabetes still need dedicated metabolic care even when hypogonadism is present.
A 2020 review in Andrology pointed out that guideline recommendations on TRT rest on a limited number of randomized trials, particularly for long-term safety in late-onset hypogonadism, and that evidence on outcomes such as worsening heart failure is lacking.[10] A follow-up survey of the T4DM trial, which gave injectable testosterone undecanoate for 2 years to men with impaired glucose tolerance or new diabetes, found no difference from placebo in self-reported new diabetes, prostate disease or cardiovascular disease about 5 years after the last injection. Sleep apnea was diagnosed more often during treatment, and more testosterone-treated men later resumed prescribed testosterone, which the authors interpreted as androgen dependence in some men.[11]
The benefits remain real in men who qualify: sexual function, body composition and bone density improve,[5] and mood may improve modestly in selected men.[6]
Myth vs fact
Myth: TRT works within days for every symptom
Fact: Effects are domain specific. Sexual interest improves within about 3 to 6 weeks, erections can take up to 6 months, body composition stabilizes at 6 to 12 months, and bone effects continue for at least 3 years.[1]
Myth: If treatment lowers body weight, it must also improve blood sugar control
Fact: Body composition and glucose control are separate outcomes. In a TRAVERSE substudy, testosterone did not significantly reduce progression from prediabetes to diabetes or increase glycemic remission in men with diabetes.[9]
Myth: Persistent erectile dysfunction always means the testosterone dose is wrong
Fact: Erection changes can take up to 6 months.[1] If they have not improved by then despite testosterone in the target range, clinicians should look for vascular, neurologic, medication-related and psychological causes, since testosterone helps sexual function mainly when hypogonadism is the driver.[4]
Myth: Fertility can be dealt with later without consequences
Fact: TRT is contraindicated in men actively seeking fertility because it suppresses gonadotropins and sperm production.[4] Men who later want children may need months to more than a year of recovery therapy. In trials, enclomiphene raised testosterone while maintaining sperm concentration, which can avoid that transition in secondary or functional hypogonadism.[3]
Bottom line
For a man with confirmed hypogonadism, sexual interest may improve within weeks and erections within about 6 months, mood may improve modestly, body composition changes over the first year, and bone effects need longer follow-up with DEXA when indicated. Follow-up labs confirm that testosterone is in range and that hematocrit and PSA stay safe. For the full diagnostic and treatment roadmap, see the Low Testosterone hub.
Veedma offers testing that includes total and free testosterone measured by LC-MS/MS with LH and FSH, or a review of labs a man already has. Licensed providers prescribe enclomiphene, or the enclomiphene plus tadalafil tablet, when appropriate and adjust treatment based on follow-up labs. Enclomiphene is not an FDA-approved drug; it is prescribed after a provider confirms the diagnosis and is compounded by a licensed U.S. pharmacy.
References
- Saad F, Aversa A, Isidori AM, et al. Onset of effects of testosterone treatment and time span until maximum effects are achieved. Eur J Endocrinol. 2011;165:675-85. PMID: 21753068
- Snyder PJ, Bhasin S, Cunningham GR, et al. Effects of Testosterone Treatment in Older Men. N Engl J Med. 2016;374:611-24. PMID: 26886521
- Kim ED, McCullough A, Kaminetsky J. Oral enclomiphene citrate raises testosterone and preserves sperm counts in obese hypogonadal men, unlike topical testosterone: restoration instead of replacement. BJU Int. 2016;117:677-85. PMID: 26496621
- Kanakis GA, Pofi R, Goulis DG, et al. EMAS position statement: Testosterone replacement therapy in older men. Maturitas. 2023;178:107854. PMID: 37845136
- Boeri L, Masterson T, Antonio L, et al. Testosterone Therapy in Adult Males with Hypogonadism. Eur Urol. 2026;90:32-43. PMID: 41448986
- Walther A, Breidenstein J, Miller R. Association of Testosterone Treatment With Alleviation of Depressive Symptoms in Men: A Systematic Review and Meta-analysis. JAMA Psychiatry. 2019;76:31-40. PMID: 30427999
- Salonia A, Capogrosso P, Boeri L, et al. European Association of Urology Guidelines on Male Sexual and Reproductive Health: 2025 Update on Male Hypogonadism, Erectile Dysfunction, Premature Ejaculation, and Peyronie’s Disease. Eur Urol. 2025;88:76-102. PMID: 40340108
- Lincoff AM, Bhasin S, Flevaris P, et al. Cardiovascular Safety of Testosterone-Replacement Therapy. N Engl J Med. 2023;389:107-117. PMID: 37326322
- Bhasin S, Lincoff AM, Nissen SE, et al. Effect of Testosterone on Progression From Prediabetes to Diabetes in Men With Hypogonadism: A Substudy of the TRAVERSE Randomized Clinical Trial. JAMA Intern Med. 2024;184:353-362. PMID: 38315466
- Barbonetti A, D’Andrea S, Francavilla S. Testosterone replacement therapy. Andrology. 2020;8:1551-1566. PMID: 32068334
- Handelsman DJ, Grossmann M, Yeap BB, et al. Long-term Outcomes of Testosterone Treatment in Men: A T4DM Postrandomization Observational Follow-up Study. J Clin Endocrinol Metab. 2023;109:e25-e31. PMID: 37623257
Low energy, low libido, or brain fog?
Order your lab panelStart with a lab panel
Get a clinical review of your results and health history, with an explanation of the decision and next steps in your patient chat. If you are eligible and want treatment, choose a plan and save a card to book a video visit at no extra visit fee. Treatment billing starts only if prescribed.
Order your lab panelPrefer short video breakdowns? Follow @veedma.men on TikTok for quick, study-backed men's hormone explainers.

Vladimir Kotlov, MD: Founder & CEO at Veedma
Vladimir Kotlov, MD is the founder of Veedma. A urologist by training, he led a urology department at a fertility and reproductive clinic where he managed a team of 30+ clinicians and improved IVF outcomes by 24%. He then moved to Silicon Valley and spent five years advising healthtech companies before founding Veedma to help men access evidence-based hormone optimization and fertility care.